Editor’s note

Urgent regulatory reform is needed to spur more proactive policies for proposed bulk drug and API parks which will make the…

Outbreaks like 2019-nCoV underline the need for more R&D investment in infectious diseases

Will the sector get their shocks post-budget, via a revamped UCPMP, further pricing woes, etc?

The over-dependence on China and other countries imperils not just the health of the pharma industry in India, but also that of…

The industry will always find ways to slip through legal loopholes. Will regulators catch up in 2020?

Wide price deviation between countries offering cheaper medications indicates the complexity of drug pricing strategies across…

With headwinds in overseas markets, it is vital for pharma companies in India to grow their presence in the domestic market. But…

While regulators and pharma companies try to understand if it is the product or the process that is at fault in the ranitidine…

Multiple warning letters call for renewed rigour to fix recurring lapses and instil a stronger quality compliance system

New and existing pharma facilities will have to meet higher benchmarks to ensure that they do not pollute the environment…